Breaking AI & Tech News Analyzed

The Arsenal Bus Parade Incident About 75 people had to be rescued from height and 16 people were arrested during Arsenal’s victory bus parade on Sunday, emergency services said. Details of the Incidents The Metropolitan police said 16 arrests had been made in the area around the parade as of 9pm on Sunday. The force said arrests had been made on charges including drunk and disorderly behaviour, drug offences, sexual assault, and assaulting emergency workers. Officers were called to the scene of a stabbing on Hornsey Road just after 8.30pm and responded with paramedics and the air ambulance. Rescue and Fire Response The London fire brigade (LFB) said it rescued “approximately 75 people” from incidents at height during the event and encouraged fans to refrain from climbing on to rooftops. It also said they attended a fire at a hotel, believed to have been caused by a stray flare. Police Response and Safety Measures Officers have been granted additional stop and search powers responding to incidents in north London around the Arsenal parade. The force said on X that a “Section 60” of the Criminal Justice and Public Order Act 1994 had been authorised overnight for police in north London. Aftermath and Warnings The LFB assistant commissioner Pat Goulbourne said: “Fortunately, the fire caused only a small amount of damage to the exterior of the building. Pyrotechnics are also believed to have triggered the fire alarms at several other locations in the area. As supporters head home, we would urge them to avoid using pyrotechnics, particularly at stations, and to keep them away from buildings and other flammable materials.”

Executive Summary of the Suppression AllegationsLast week the New York Times and Washington Post disclosed that the FDA directed the withdrawal of two Covid‑19 vaccine safety studies and blocked a Shingrix safety abstract, despite peer‑review acceptance. The actions raise serious questions about political interference in vaccine safety surveillance.FDA Withdraws Peer‑Reviewed Vaccine Safety StudiesIn October, FDA scientists were instructed to pull two manuscripts that had been accepted by the journals Drug Safety and Vaccine. A February decision prevented the submission of Shingrix safety abstracts to a major drug‑safety conference. The agency commissioned the work, received the findings, but has not released them.Scale of the Suppressed Studies and Their FindingsStudy 1 examined 7.5 million Medicare beneficiaries for 14 pre‑specified adverse outcomes after 2023‑2024 Covid‑19 vaccination, using a self‑controlled case‑series design with up to 90 days follow‑up. Only anaphylaxis (~1 per million Pfizer‑BioNTech doses) rose above statistical noise.Study 2 analyzed 4.2 million recipients aged 6 months to 64 years, confirming rare febrile‑seizure and myocarditis signals already on product labels.The Shingrix analysis, covering millions, reaffirmed a low but elevated Guillain‑Barré risk noted on the vaccine’s package insert.Implications for Public‑Health Transparency Ahead of the World CupThe timing coincides with the 2026 FIFA World Cup across 11 U.S. host cities, a period when measles cases have surged to >9,000 in Mexico and Canada lost measles‑elimination status. The CDC has lost roughly a quarter of its workforce in the past year and has faced editorial pressure on its weekly reports. Suppressing reassuring safety data while allowing unsubstantiated adverse‑event claims to circulate undermines clinician confidence and public‑health surveillance.Future Outlook for Vaccine Surveillance and PolicyIf political appointees continue to block peer‑reviewed findings, the credibility of federal vaccine monitoring could erode, prompting calls for independent oversight or legislative action. Transparency of the existing data may become a focal point for lawmakers and health‑care professionals as the World Cup progresses and respiratory clusters emerge.

Scientists from University College London and partners have proved that a 50‑gene genomic test can reliably pinpoint hormone‑positive breast‑cancer patients who do not need chemotherapy, potentially sparing millions from toxic side‑effects.Optima Trial Demonstrates Genomic Test Can Identify Low‑Risk PatientsThe Optima trial enrolled 4,429 women aged 40+ across the UK, Norway, Sweden, Australia, New Zealand and Thailand. Participants were split into a standard‑care arm (chemotherapy + hormone therapy) and a test‑guided arm where treatment was decided by the genomic score.Trial Numbers Reveal Near‑Identical Survival RatesFive‑year outcomes were strikingly similar:95% of patients receiving chemotherapy remained alive and recurrence‑free.94% of patients who skipped chemotherapy (low‑score group) were also alive and recurrence‑free.The test classified patients using a score derived from the activity of 50 tumour genes, produced by Veracyte's Prosigna assay.These figures indicate that for low‑score patients, chemotherapy adds little or no survival benefit.Potential Shift in Breast Cancer Treatment GuidelinesProf Rob Stein, chief investigator, says the results “address a longstanding challenge” by moving decision‑making from clinical features to tumour biology. Health systems could see reduced drug costs, fewer hospital visits, and a dramatic drop in chemotherapy‑related toxicity.Future Adoption and Healthcare SavingsWith funding from the NIHR, Veracyte and cancer charities, the study paves the way for rapid guideline updates at bodies like ASCO and NICE. Wider implementation could translate into billions of dollars saved globally and improve quality of life for countless patients. Ongoing monitoring will confirm long‑term outcomes, but the early data suggest a new era of personalised, cost‑effective breast‑cancer care.

Colombian Voters Head to Polls in First Round of Presidential RacePolls opened across the country for the inaugural round of Colombia’s presidential election, featuring a left‑wing lawmaker, an independent businessman and a right‑wing senator vying to succeed President Gustavo Petro. A heavy security presence and a ban on public alcohol sales aim to keep tensions low. Poll Numbers and Candidate StandingsIvan Cepeda (government‑aligned senator) – 33.4% in the latest CNC poll, currently the frontrunner.Abelardo De La Espriella (businessman) – second place, campaigning on hard‑line security and megaprison projects.Paloma Valencia (senator backed by former President Alvaro Uribe) – third, would become Colombia’s first female president if elected.Fourteen candidates in total are contesting the presidency. If no one surpasses the 50% threshold, the top two will face a runoff on June 21. Implications for Colombia’s Political Landscape and SecurityThe result will gauge the durability of Petro’s left‑wing legacy, including his “Total Peace” negotiations with armed groups. A Cepeda victory could extend Petro’s social‑reform agenda, while a win for De La Espriella or Valencia would likely shift policy toward a tougher security stance, echoing approaches seen in El Salvador.Violence remains a concern; last year candidate Miguel Uribe Turbay was assassinated, underscoring the persistent threat from paramilitaries, drug cartels and rebel factions. What the First Round Results Could Mean for a Run‑offShould the vote fall short of the 50% mark, a June runoff will force the left‑wing and right‑wing blocs to consolidate around a single contender, potentially reshaping alliances. Analysts warn that a fragmented right could coalesce behind a hard‑line candidate, while the left may need to rally behind Cepeda to preserve Petro’s reforms.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Rise of Nigeria's Digital Herbal Marketplace In Abuja, Nigeria, Oke Bola thought a fertility supplement she found online might help her conceive. Instead, within days of taking it, she struggled to breathe. Her experience reflects a growing online trade in unverified herbal remedies promoted across social media platforms. Bola, who is in her early 40s and has never had children, bought the supplement earlier this year and increased the recommended dosage, hoping for quicker results after hearing about it from friends and family. "I recognised the symptoms of asthma; the wheezing sound at night was familiar," she told Al Jazeera. "When I checked online, I realised it could be from the herbal medication." Her experience is not isolated. Across Nigeria, doctors and pharmacists report a surge in social media-driven self-medication, particularly involving unverified herbal products. This trend is worsening health outcomes, delaying treatment, and adding pressure to an already strained healthcare system serving about 230 million people. Nigeria's young, hyperconnected population increasingly uses digital platforms for health information and advice. But that access has also created what Dr Isaac Kolawole and Dr Fidelis describe as an "algorithmic apothecary" – an unregulated online marketplace where influencers and anonymous sellers promote remedies directly to consumers with little or no scientific backing. Health Impacts of Unverified Herbal Remedies Within this ecosystem, herbal remedies, long part of Nigeria's medical and cultural landscape, are increasingly repackaged as miracle cures, sometimes with dangerous consequences. Doctors report more patients arriving at hospitals only when their conditions have significantly worsened, often after prolonged use of unverified treatments. A consultant nephrologist at the University College Hospital in Ibadan, Dr Yemi Raji, said herbal medicine continues to play a role in kidney disease cases in Nigeria. "When you take herbal medication, you are taking both the good and the bad," he said. "Patients often arrive late, when treatment is more difficult and expensive." Dialysis alone can cost between 50,000 and 100,000 naira ($36-72) per session, several times a week. Studies link herbal use to kidney and liver disease cases across Africa, including findings that about 46 percent of liver disease admissions in one Nigerian hospital involved herbs or roots. A 2022 study found that 76.65 percent of participants had used herbal medicine, with more than a third combining herbal and conventional treatments while 82.44 percent did not inform their doctors. The Algorithmic Amplification Effect On a smartphone screen, relief is just a click away: fertility tonics, eye drops promising restored vision, syrups claiming to "flush out" disease. The advertisements are polished, persuasive and constant, woven into TikTok, Facebook, Instagram and X feeds. "The platforms themselves amplify this effect," said Dr Egemba Chinonso Fidelis, a public health advocate known online as Aproko Doctor. "Their algorithms reward engaging content and push it to wider audiences." Even users who try to avoid such content often encounter it repeatedly, shaped by emotional storytelling, music and urgency-driven messaging. A 2025 Nigeria-based study on Jinja Herbal Mixture found it appeared safe for short-term use within tested dosage ranges, but researchers recorded biochemical changes at higher doses, including altered creatinine and sodium levels in test subjects, signs of possible kidney and liver stress. The study called for further research into long-term effects and interactions with conventional medicines. Regulatory Challenges in the Digital Age The National Agency for Food and Drug Administration and Control (NAFDAC) says it is working to track unregistered manufacturers, but enforcement remains difficult, especially online. "With the sheer volume of products online, enforcement has limited reach," said Isaac Kolawole, the southwest zonal director of NAFDAC. Many sellers use fake or incomplete addresses, making them difficult to trace. NAFDAC requires strict registration, testing and approval before herbal products can be sold or advertised, but regulation has not kept pace with online commerce. Fidelis argued that stronger regulation alone is not enough. "If there are no consequences for lying about healthcare online, people will keep doing it," he said. He noted that scammers have even used AI-generated versions of his image to promote fake products. "Real medicine does not promise to cure everything, and it does not rely on countdowns," he added. "Scammers do." Path Forward for Safer Digital Health As Nigeria's digital economy expands, the intersection of technology and healthcare will only grow more complex. Fidelis stressed that access to affordable healthcare must improve, public trust must be rebuilt, and digital platforms must take responsibility for the health content they amplify. Pharmacist Akinade Akinlolu noted that while conditions like diabetes and hypertension can be managed, online claims often suggest cures. "Economic pressure is also pushing people towards cheaper or 'miracle' alternatives," he added. "Without stronger safeguards," Fidelis warned, "the algorithmic apothecary will continue to grow and put more people at risk." The challenge for Nigeria's healthcare system is to harness the power of digital platforms while ensuring they promote evidence-based care rather than potentially harmful alternatives.

The Viral Image That Wasn't RealIt was an arresting image and an irresistible story. A group of tough Thai police officers – five men and one woman – all wearing elaborate festival-style dresses, surrounding a drug dealer they had caught while undercover. The image, released by local police, was so compelling that it found its way on to the front page of the UK's Daily Star, as well as in picture stories in the Telegraph, the Sun and the New York Post.The Sun wrote: "The burly crew of five men and one woman slipped into skin tight sequins and feathers for the covert mission in Thailand." The Daily Star wrote: "The team of five blokes and one woman shared a snap of themselves in frilly dresses with the nicked suspect on Facebook."There was just one problem: while the arrest was real, the image was an AI-generated fake.The Digital Deception Behind the Sparkly DressesThe real image, which has now been posted on the Facebook page of Tha Luang police station in Thailand, shows the five male police officers in their regular clothes. The woman dressed as a dancer is not in the original at all.The administrator in charge of the station's Facebook account, which released the AI-generated image, had been trying to create "a friendlier image" for the police, intending to show "a cute and humorous side". This attempt at humanizing law enforcement through digital manipulation inadvertently created a false narrative that spread internationally.The Media Verification Challenge in the AI EraThe absurdity of the image may have rung alarm bells with some readers. However, the fact that the faked image came from a seemingly official source has highlighted the difficulties media outlets face in verifying images.There are no foolproof ways to check whether an image is real without a direct relationship with the person who took the picture. It is becoming a time-consuming and precarious task for those overseeing the images used by large outlets, and AI verification tools are not reliable enough.Industry Implications for News OrganizationsThe problem is made even more difficult as the use of AI-generated imagery has crept into seemingly official sources. As a result, editors are braced for the reality that it is unlikely that all AI images will be spotted before publication.Media outlets and other organisations are also facing the opposite problem – with viewers wrongly suspecting that some genuine images have been generated with AI. This creates a credibility crisis where authentic content is increasingly questioned while manipulated content gains acceptance.The Future of Visual AuthenticationAs AI technology continues to advance, the line between real and fabricated content will become increasingly blurred. News organizations will need to invest in more sophisticated verification methods and potentially develop new standards for image authentication.The incident in Thailand serves as an early warning of the challenges ahead in maintaining journalistic integrity in an era where digital content can be convincingly altered with minimal technical skill. The media industry may need to adopt new protocols for image verification and be more transparent about the sources of their visual content.

Former England international Raheem Sterling was arrested on the M3 motorway on 28 May 2026, and a source close to the player says the incident has left him feeling “disposable” after ten years at the top of the game.Sterling’s Arrest on the M3 Sparks Public ScrutinyLocation: Southbound carriageway of the M3 near Minley Interchange, Hampshire.Time: Just before 9 am.Charges: Suspicion of driving while unfit through drugs, dangerous driving, possession of a class C drug, and failing to provide a specimen.Status: Bailed while investigations continue.Financial Context: Contract Value and Club DepartureThe source noted that Sterling left Chelsea by mutual consent in January 2026, despite having 18 months remaining on a contract worth £325,000 a week. He subsequently joined Dutch side Feyenoord, seeking a fresh start away from the English spotlight.Psychological Toll and Media Narrative on Black FootballersAccording to the insider, Sterling has endured “immeasurable” psychological strain over “an extremely tough couple of years”, compounded by persistent racist abuse and what he perceives as disproportionate media criticism of black players. The source argues the episode highlights a broader issue: players who are no longer “fit for purpose” are treated as disposable.What Lies Ahead for Sterling’s Career and ReputationWhile the police investigation proceeds, Sterling’s future hinges on both legal outcomes and his ability to rebuild confidence at Feyenoord. The source stresses that the arrest is “under suspicion” with no proof of drug influence, suggesting the narrative could shift if cleared. Observers will watch how clubs, sponsors, and the media respond, potentially influencing how former Premier League stars are supported during career transitions.